6 days Ago By ABMN Staff
Franklin Resources Inc. lowered its stake in shares of Moderna, Inc. ( NASDAQ:MRNA – Free Report ) by 2.
0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,141 shares of the company’s stock after selling 602 shares during the quarter. Franklin Resources Inc.
’s holdings in Moderna were worth $1,253,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Orion Portfolio Solutions LLC grew its stake in Moderna by 65.
1% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 3,661 shares of the company’s stock valued at $245,000 after buying an additional 1,443 shares during the last quarter. MML Investors Services LLC boosted its holdings in Moderna by 21.
6% during the third quarter. MML Investors Services LLC now owns 33,895 shares of the company’s stock valued at $2,265,000 after acquiring an additional 6,018 shares during the period. Inspire Trust Co.
N.A. grew its position in shares of Moderna by 73.
5% in the third quarter. Inspire Trust Co. N.
A. now owns 16,525 shares of the company’s stock valued at $1,104,000 after purchasing an additional 7,000 shares during the last quarter. Principal Financial Group Inc.
increased its stake in shares of Moderna by 4.2% in the third quarter. Principal Financial Group Inc.
now owns 379,451 shares of the company’s stock worth $25,359,000 after purchasing an additional 15,218 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Moderna by 31.9% during the 4th quarter.
GAMMA Investing LLC now owns 3,173 shares of the company’s stock worth $132,000 after purchasing an additional 768 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.
Analyst Ratings Changes A number of analysts have issued reports on MRNA shares. Leerink Partners lowered their target price on Moderna from $31.00 to $27.
00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th.
UBS Group cut their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th.
The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th.
Finally, Citigroup assumed coverage on shares of Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price objective for the company.
Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $58.
70. Moderna Stock Performance Shares of NASDAQ MRNA opened at $26.80 on Tuesday.
Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.
47. The business has a fifty day moving average of $31.40 and a two-hundred day moving average of $40.
57. The stock has a market cap of $10.36 billion, a PE ratio of -2.
89 and a beta of 2.23. Moderna Profile ( Free Report ) Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. See Also Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc.
( NASDAQ:MRNA – Free Report ). Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter .
.
